These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 9676215)

  • 21. Repeat prostate needle biopsy: who needs it?
    Ellis WJ; Brawer MK
    J Urol; 1995 May; 153(5):1496-8. PubMed ID: 7536254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
    Yang JC; Tang J; Li J; Luo Y; Li Y; Shi H
    Acad Radiol; 2008 Oct; 15(10):1291-7. PubMed ID: 18790401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
    Pelzer A; Bektic J; Berger AP; Pallwein L; Halpern EJ; Horninger W; Bartsch G; Frauscher F
    J Urol; 2005 Jun; 173(6):1926-9. PubMed ID: 15879783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic value of 10 systematized and ultrasound-guided transrectal prostatic biopsies].
    Ravery V; Billebaud T; Toublanc M; Boccon-Gibod L; Hermieu JF; Moulinier F; Blanc E; Delmas V; Boccon-Gibod L
    Prog Urol; 1998 Dec; 8(6):1012-7. PubMed ID: 9894260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.
    Stamey TA; Yemoto CE
    J Urol; 2000 Jan; 163(1):119-26. PubMed ID: 10604328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
    Ferda J; Kastner J; Hora M; Hes O; Fínek J; Topolčan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Screening of prostate carcinoma].
    Trinkler FB
    Ther Umsch; 1995 Jun; 52(6):393-8. PubMed ID: 7541568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.
    Ko JS; Landis P; Carter HB; Partin AW
    BJU Int; 2011 Dec; 108(11):1739-42. PubMed ID: 21736692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
    Littrup PJ
    Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL.
    Ito K; Ohi M; Yamamoto T; Miyamoto S; Kurokawa K; Fukabori Y; Suzuki K; Yamanaka H
    Cancer; 2002 Nov; 95(10):2112-9. PubMed ID: 12412164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The change in serum Thiol/Disulphide homeostasis after transrectal ultrasound guided prostate biopsy.
    Tokgöz H; Taş S; Giray Ö; Yalçınkaya S; Tokgöz Ö; Koca C; Savaş M; Erel Ö
    Int Braz J Urol; 2017; 43(3):455-461. PubMed ID: 28128906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transrectal biopsy of the prostate guided by transrectal ultrasound.
    Torp-Pedersen ST; Lee F
    Urol Clin North Am; 1989 Nov; 16(4):703-12. PubMed ID: 2683300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia.
    Lee F; Torp-Pedersen ST; Carroll JT; Siders DB; Christensen-Day C; Mitchell AE
    Urology; 1989 Dec; 34(6 Suppl):4-8. PubMed ID: 2481362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.